Engineered Dendritic Cell Vaccines for Multiple Myeloma
ConditionMultiple Myeloma or Plasmacytoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Eligibility criteria
Qualifiers
Male and female subjects with multiple myeloma or plasmacytoma
Very good partial or complete remission (CR) after prior combination therapies.
Expected survival > 12 weeks
Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal
Disqualifiers
Pregnant or lactating women
Uncontrolled active infection
HIV or active hepatitis B or hepatitis C infection
Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
Trial design
Treatments tested in this trial
- DC vaccines
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov